Effect of Bifidobacterium Breve B-3 on Body Fat in Obese Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03774381|
Recruitment Status : Completed
First Posted : December 13, 2018
Last Update Posted : September 11, 2019
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Dietary Supplement: Bifidobacterium breve B-3 Dietary Supplement: Control group||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Bifidobacterium Breve B-3 on Body Fat in Obese Adults|
|Actual Study Start Date :||September 1, 2018|
|Actual Primary Completion Date :||July 31, 2019|
|Actual Study Completion Date :||August 1, 2019|
Experimental: Bifidobacterium breve B-3 group
160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
Dietary Supplement: Bifidobacterium breve B-3
160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
Placebo Comparator: Control group
160 mg of placebo was orally administered per day for 12 weeks.
Dietary Supplement: Control group
160 mg of placebo is orally administered per day for 12 weeks.
- Body fat [ Time Frame: Change from baseline body fat at 12 weeks ]dual energy x-ray absorptiometry (DEXA)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03774381
|Korea, Republic of|
|Integrated Research Institute for Natural Ingredients and Functional Foods|
|Yangsan, Korea, Republic of, 50612|
|Principal Investigator:||Sang Yeoup Lee, MD||Pusan National University Yangsan Hospital|